Neurocrine Biosciences Prepares for 2025 R&D Day to Highlight Neuroscience Innovations

Neurocrine Biosciences Prepares for 2025 R&D Day to Showcase Neuroscience Advances

Neurocrine Biosciences, Inc. is set to host its 2025 Research and Development Day on December 16, 2025, at 12:00 p.m. Eastern Time in San Diego, focusing on the company’s ongoing transformation in research and development as well as its expanding pipeline in neuroscience. This event promises to be significant, featuring prominent figures in the field such as Dr. John Krystal from Yale University, who is known for his expertise in neuropsychiatric disorders. Neurocrine's management aims to provide insights into their innovative strategies and the future of treatment options for neurological conditions, which align with the company’s mission to alleviate suffering through scientific advancement.

The upcoming R&D Day serves as a platform for Neurocrine to highlight its commitment to developing treatments for a range of conditions, including neurological, neuroendocrine, and neuropsychiatric disorders. The company has built a solid portfolio over the last thirty years, achieving FDA approval for therapies targeting tardive dyskinesia and chorea associated with Huntington's disease, among others. As Neurocrine continues to evolve, it emphasizes the importance of understanding the intricate connections between brain and body systems, which underpins its approach to creating life-changing treatments.

Moreover, the event will allow participants to access a live webcast, showcasing the company’s dedication to transparency and stakeholder engagement. A replay of the event and supplemental materials will be available for an extended period following the presentation, ensuring that crucial information reaches a broader audience. This commitment to sharing knowledge not only reflects Neurocrine's leadership in the biopharmaceutical sector but also its goal to foster collaboration and innovation within the neuroscience community.

In addition to its upcoming R&D Day, Neurocrine remains focused on advancing its robust pipeline, which includes several compounds currently in mid- to late-phase clinical development. This focus underscores the company’s dedication to tackling complex medical conditions through groundbreaking research and innovative solutions. Stakeholders and interested parties are encouraged to stay informed by visiting Neurocrine's official website and following the company on social media platforms like LinkedIn, X, and Facebook.